Author: admin

Woehrer, A., Bauchet, L. & Barnholtz-Sloan, J. S. Glioblastoma survival: Has it improved? Evidence from population-based studies. Curr. Opin. Neurol. 27, 666–674. https://doi.org/10.1097/wco.0000000000000144 (2014).

Google Scholar 

Kan, L. K. et al. Potential biomarkers and challenges in glioma diagnosis, therapy and prognosis. BMJ Neurol. Open 2, e000069. https://doi.org/10.1136/bmjno-2020-000069 (2020).

Google Scholar 

Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996. https://doi.org/10.1056/NEJMoa043330 (2005).

Google Scholar 

Friedman, H. S. et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J. Clin. Oncol. 27, 4733–4740. https://doi.org/10.1200/jco.2008.19.8721 (2009).

Google Scholar 

Kreisl, T. N. et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J. Clin. Oncol. 27, 740–745. https://doi.org/10.1200/jco.2008.16.3055 (2009).

Google Scholar 

Cohen, M. H., Shen, Y. L., Keegan, P. & Pazdur, R. FDA drug approval summary: Bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. Oncologist 14, 1131–1138. https://doi.org/10.1634/theoncologist.2009-0121 (2009).

Google Scholar 

Ferrara, N., Hillan, K. J., Gerber, H.-P. & Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391–400. https://doi.org/10.1038/nrd1381 (2004).

Google Scholar 

Chinot, O. L. et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 709–722. https://doi.org/10.1056/NEJMoa1308345 (2014).

Google Scholar 

Gilbert, M. R. et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N. Engl. J. Med. 370, 699–708. https://doi.org/10.1056/NEJMoa1308573 (2014).

Google Scholar 

Schmainda, K. M. et al. Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: Results from ACRIN 6686 multicenter trial. Neuro Oncol. 23, 314–323. https://doi.org/10.1093/neuonc/noaa167 (2021).

Google Scholar 

Xu, L. et al. COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci. Transl. Med. 6, 242ra284-242ra284 (2014).

Google Scholar 

Macarulla, T. et al. Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: Clinical and biomarker data from the randomized phase II IMbrave151 trial. J. Clin. Oncol. 43, 545–557 (2024).

Google Scholar 

Loureiro, L. V. M. et al. The immunohistochemical landscape of the VEGF family and its receptors in glioblastomas. Surg. Exp. Pathol. 3, 1–8 (2020).

Google Scholar 

Jin, K., Qian, C., Lin, J. & Liu, B. Cyclooxygenase-2-Prostaglandin E2 pathway: A key player in tumor-associated immune cells. Front. Oncol. 13, 1099811. https://doi.org/10.3389/fonc.2023.1099811 (2023).

Google Scholar 

Xu, L. & Croix, B. S. Improving VEGF-targeted therapies through inhibition of COX-2/PGE2 signaling. Mol. Cell Oncol. 1, e969154. https://doi.org/10.4161/23723548.2014.969154 (2014).

Google Scholar 

Shono, T., Tofilon, P. J., Bruner, J. M., Owolabi, O. & Lang, F. F. Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res. 61, 4375–4381 (2001).

Google Scholar 

Zhang, F., Chu, J. & Wang, F. Expression and clinical significance of cyclooxygenase 2 and survivin in human gliomas. Oncol. Lett. 14, 1303–1308. https://doi.org/10.3892/ol.2017.6281 (2017).

Google Scholar 

Wang, X. et al. Co-expression of COX-2 and 5-LO in primary glioblastoma is associated with poor prognosis. J. Neurooncol. 125, 277–285. https://doi.org/10.1007/s11060-015-1919-6 (2015).

Google Scholar 

Hicklin, D. J. & Ellis, L. M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23, 1011–1027. https://doi.org/10.1200/jco.2005.06.081 (2005).

Google Scholar 

Qiu, J., Shi, Z. & Jiang, J. Cyclooxygenase-2 in glioblastoma multiforme. Drug Discov. Today 22, 148–156. https://doi.org/10.1016/j.drudis.2016.09.017 (2017).

Google Scholar 

Lu-Emerson, C. et al. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma. J. Clin. Oncol. 33, 1197–1213. https://doi.org/10.1200/jco.2014.55.9575 (2015).

Google Scholar 

Motomura, K. et al. Cost of medical care for malignant brain tumors at hospitals in the Japan clinical oncology group brain-tumor study group. Jpn. J. Clin. Oncol. 54, 1123–1131. https://doi.org/10.1093/jjco/hyae116 (2024).

Google Scholar 

Hashemi Goradel, N., Najafi, M., Salehi, E., Farhood, B. & Mortezaee, K. Cyclooxygenase-2 in cancer: A review. J. Cell Physiol. 234, 5683–5699. https://doi.org/10.1002/jcp.27411 (2019).

Google Scholar 

Lin, P. C., Lin, Y. J., Lee, C. T., Liu, H. S. & Lee, J. C. Cyclooxygenase-2 expression in the tumor environment is associated with poor prognosis in colorectal cancer patients. Oncol. Lett. 6, 733–739 (2013).

Google Scholar 

Shi, C. et al. High COX-2 expression contributes to a poor prognosis through the inhibition of chemotherapy-induced senescence in nasopharyngeal carcinoma. Int. J. Oncol. 53, 1138–1148. https://doi.org/10.3892/ijo.2018.4462 (2018).

Google Scholar 

Kambe, A. et al. The utility of arterial spin labeling imaging for predicting prognosis after a recurrence of high-grade glioma in patients under bevacizumab treatment. J. Neurooncol. 166, 175–183. https://doi.org/10.1007/s11060-023-04550-w (2024).

Google Scholar 

Lombardi, F. et al. Cyclooxygenase-2 upregulated by temozolomide in glioblastoma cells is shuttled in extracellular vesicles modifying recipient cell phenotype. Front. Oncol. 12, 933746. https://doi.org/10.3389/fonc.2022.933746 (2022).

Google Scholar 

Lombardi, F. et al. Up-regulation of cyclooxygenase-2 (COX-2) expression by temozolomide (TMZ) in human glioblastoma (GBM) cell lines. Int. J. Mol. Sci. https://doi.org/10.3390/ijms23031545 (2022).

Google Scholar 

Schmainda, K. M. et al. Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma. Neuro Oncol. 16, 880–888. https://doi.org/10.1093/neuonc/not216 (2014).

Google Scholar 

Leu, K. et al. Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab. Cancer Imaging 14, 31. https://doi.org/10.1186/s40644-014-0031-z (2014).

Google Scholar 

Kickingereder, P. et al. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma. Neuro Oncol. 17, 1139–1147. https://doi.org/10.1093/neuonc/nov028 (2015).

Google Scholar 

Liu, T. T. et al. Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment. Neuro Oncol. 19, 997–1007. https://doi.org/10.1093/neuonc/now270 (2017).

Google Scholar 

Bennett, I. E. et al. Early perfusion MRI predicts survival outcome in patients with recurrent glioblastoma treated with bevacizumab and carboplatin. J. Neurooncol. 131, 321–329. https://doi.org/10.1007/s11060-016-2300-0 (2017).

Google Scholar 

Schmainda, K. M. et al. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: Results from the ACRIN 6677/RTOG 0625 multicenter trial. Neuro Oncol. 17, 1148–1156. https://doi.org/10.1093/neuonc/nou364 (2015).

Google Scholar 

Alves, B. et al. High VEGFA expression is associated with improved progression-free survival after bevacizumab treatment in recurrent glioblastoma. Cancers https://doi.org/10.3390/cancers15082196 (2023).

Google Scholar 

Rawat, C. et al. Downregulation of peripheral PTGS2/COX-2 in response to valproate treatment in patients with epilepsy. Sci. Rep. 10, 2546. https://doi.org/10.1038/s41598-020-59259-x (2020).

Google Scholar 

Est-Witte, S. E. et al. Non-viral gene delivery of HIF-1α promotes angiogenesis in human adipose-derived stem cells. Acta Biomater. 113, 279–288. https://doi.org/10.1016/j.actbio.2020.06.042 (2020).

Google Scholar 

Wen, P. Y. et al. Updated response assessment criteria for high-grade gliomas: Response assessment in neuro-oncology working group. J. Clin. Oncol. 28, 1963–1972. https://doi.org/10.1200/jco.2009.26.3541 (2010).

Google Scholar